

# Navigating Lung Cancer Screening

## Identifying and Engaging High-Risk Individuals

Provided by **AA<sup>®</sup>CME**  
AMERICAN ACADEMY OF CME, INC.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Accredited Continuing Education

Release date: January 31, 2025 • Expiration date: January 31, 2026

Estimated time to complete: 0.75 hour




### Why Participate

Despite the clear advantages of screening for early-stage, more treatable lung cancer, a surprisingly low percentage of eligible Americans undergo recommended screening. While current guidelines for lung cancer screening are largely consistent, the nuances in interpreting and applying these criteria to the patient in front of you can be perplexing, leading to lower screening rates. Utilizing clinical cases and related questions, **faculty educator Carla Lamb, MD, FACP, FCCP (Lahey Hospital & Medical Center)**, addresses these key points, offering guidance on how to identify high-risk patients suitable for screening. Additionally, it will provide strategies to facilitate shared decision-making with patients, focusing on a comprehensive discussion of the benefits and risks associated with screening.

At the conclusion of the webinar, learners should be better able to:

- Review the evidence supporting CT lung screening benefits for eligible individuals in high-risk categories
- Utilize current recommendations to identify candidates for lung cancer screening
- Determine next steps to obtaining lung cancer screening for eligible patients
- Identify and address barriers to lung cancer screening in eligible patients
- Assess care team management to lung cancer screening

### Activity Faculty



**Carla Lamb, MD, FACP, FCCP**

Co-founder, Multi-Disciplinary Thoracic Oncology Clinic

Director, Interventional Pulmonary Medicine

Director, Interventional Pulmonology Fellowship Program Director

Lahey Hospital & Medical Center

**Target Audience:** This activity is intended for pulmonologists. Other physicians, NPs and PAs who provide primary care services to persons who may be at risk for lung cancer are also encouraged to participate.

## Accreditation and Credit Designation



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians:** American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



### American Board of Internal Medicine Maintenance of Certification Credits

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By claiming MOC points, you are agreeing to have your participation completion information to be shared with the ACCME and the ABIM. Your points will be automatically submitted to the ABIM on your behalf; please allow 6-8 weeks for your points to display on the ABIM website.

**CLAIMING MOC POINTS:** If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number when completing your evaluation. Physicians who do not know their ABIM ID can look it up on ABIM's website <https://www.abim.org/online/findcand.aspx>.

**Other Team Members:** Other members of the care team will receive a certificate of participation.

**Method of Participation:** There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the post-test, and program evaluation. Your certificate will be emailed to you within 24 hours.

**Contact:** For any questions, please contact: [CEServices@academycme.org](mailto:CEServices@academycme.org)

**Faculty Bio:** Carla Lamb, MD, FACP, FCCP, and the President of the American Association for Advanced Bronchology and Interventional Pulmonology. She is one of the co-founders of the Multi-Disciplinary Thoracic Oncology Clinic and Director of Interventional Pulmonary Medicine as well as the Interventional Pulmonology Fellowship Program Director at Lahey Hospital & Medical Center. Dr. Lamb is on the steering committee of the Lahey Lung Screening Program and Research committee as well as the member of the Founding Board of Directors for the Rescue Lung Society for CT Lung Screening. Dr. Lamb co-founded Women in Interventional Pulmonology. She is an internationally recognized educator, speaker and researcher in interventional pulmonology, lung cancer screening, early detection of lung cancer utilizing biomarker technology, minimally invasive diagnosis and management of pulmonary nodules, and gender differences in lung cancer. She has won numerous distinguished educator awards and is the recipient of the Pasquale Ciaglia award in Interventional Pulmonary, ALA Chadwick Award, and the Samuel Moschella Educator of the Year award. She is the pulmonary lead physician for development of the incidental lung nodule program for Beth Israel and Lahey Health. She is also participating as a principal investigator in the multi-center Nightingale study for nasal brush risk stratification of patients with indeterminate pulmonary nodules with history of tobacco use. Dr. Lamb has

been the principal investigator for the multi-center rheoplasty trial for COPD and chronic bronchitis and Airflow 3 for COPD. She has served as the director and founder of the Lahey COPD bronchoscopic lung volume reduction program for emphysema. She has co-authored the American Thoracic Society/ American College of Chest Physicians policy statement on implementation of low-dose computed tomography lung cancer screening programs in clinical practice as well as the American College of Chest Physicians guidelines for endobronchial ultrasound bronchoscopy. She has served on the national Chest Bronchoscopy Simulation Task Force. She is associate director of simulation at Lahey Hospital & Medical Center and has developed numerous national and international bronchoscopy and thoracic procedure curriculum and procedure based guidelines in bronchoscopy, image guided thoracic procedure simulation training and interventional pulmonology training. Her work has led to validation of internationally adopted procedural assessment tools. She is both the director of the interventional pulmonary program and interventional pulmonary fellowship program at Lahey Hospital and Medical Center.

**Disclosures:** According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty Educator/Planner Carla Lamb, MD, has no relevant relationships with ineligible companies to disclose. All other planners and reviewers have no relevant financial relationships with ineligible companies to disclose.

This activity will not review off-label or investigational information.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

**Hardware/Software Requirements:** Current web browser versions of any mobile, windows 10 + or Mac platforms installed.


**Privacy:** For more information about the American Academy of CME privacy policy, please access <http://www.academycme.org/privacy.htm>

**Copyright:** © 2025.

Risk Criteria			
	USPSTF <sup>1</sup>	NCCN <sup>2</sup>	ACS <sup>3</sup>
Last updated	2021	2023	2023
Age (years)	50-80	≥50	50-80
Smoking history (pack-years)	≥20	≥20	≥20
Smoking status	Current or quit in past 15 years	Current or quit in past 14 years	Current or quit

ACS, American Cancer Society; NCCN, National Comprehensive Cancer Network; USPSTF, United States Preventive Services Task Force

1. US Preventive Services Task Force. Final recommendation statement, lung cancer: screening. [www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening). 2. NCCN Guidelines. Lung Cancer Screening. Version 1.2025 — October 14, 2024. Available at [https://www.nccn.org/professionals/physician\\_gls/pdf/lung\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf). 3. Wolf AMD, et al. *CA Cancer J Clin*. 2024;74(1):50-81. doi: 10.3322/caac.21811. Epub 2023 Nov 1. Available at <https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21811>

 AACME  
AMERICAN ACADEMY OF CME, INC.